Company Says It Gave Price Exclusive Stock Deal, Contrary To His Testimony

Representative Tom Price (R-GA) testifies during the nomination hearings to be considered for Secretary of Health and Human Services, in the Dirksen Senate Office Building, in Washington, DC on January 18, 2017 (Phot... Representative Tom Price (R-GA) testifies during the nomination hearings to be considered for Secretary of Health and Human Services, in the Dirksen Senate Office Building, in Washington, DC on January 18, 2017 (Photo by Riccardo Savi) *** Please Use Credit from Credit Field ***(Sipa via AP Images) MORE LESS
Start your day with TPM.
Sign up for the Morning Memo newsletter

An Australian pharmaceutical company says it gave President Donald Trump’s nominee to lead the Department of Health and Human Services an exclusive deal to purchase stock, the Wall Street Journal reported Monday.

That directly contradicts Price’s testimony in his confirmation hearings that discounted shares of Innate Immunotherapeutics Ltd. “were available to every single individual that was an investor at the time.”

Innate Immuno CEO Simon Wilkinson said in an interview with the Journal that those investors who had previously participated in private placement had been invited to “make friends and family aware of the opportunity” to buy discounted shares.

The Journal confirmed the exclusive discount in an interview with Rep. Chris Collins (R-NY), who owns a 17 percent stake in the company and who made Price aware of the stock opportunity.

Price was one of just six “friends and family” of investors previously involved in a private placement that were offered the special discounted rates, according to the report. The Journal noted that “about 10” investors who previously purchased Innate Immuno stock were also offered discount rates, in addition to all investors in Australia and New Zealand.

Prior to the Journal report, Price was already in hot water for the timing of his initial investment in Innate Immuno. He introduced legislation that would have benefitted the company after buying up to $15,000 in stock in the company in March of last year.

After that initial investment, Price invested larger sums in Innate Immuno stock at discounted rates, according to the Journal report. On two separate occasions, Price invested a net of $50,000-$100,000, according to disclosure forms.

The Senate Finance Committee is scheduled to vote Tuesday on Price’s nomination to lead HHS.

Latest Livewire
94
Show Comments

Notable Replies

  1. New Drumpf Cabinet nominee / staff portrait. One size fits all…

  2. yawn

    What’s a standard corporate thief when we have full-blown Nazis in charge?

  3. Wait and watch. This would have sunk any prior cabinet nominee, but in our new, post ethics, post fact, post rule of law world, he’ll breeze through with flying colors.

  4. Avatar for jinnj jinnj says:
    • stay tuned - somebody at that company will be arrested for telling the truth.

Continue the discussion at forums.talkingpointsmemo.com

88 more replies

Participants

Avatar for valgalky23 Avatar for dr_coyote Avatar for ajaykalra Avatar for overreach_this Avatar for ncsteve Avatar for clunkertruck Avatar for commiedearest Avatar for steviedee111 Avatar for inlabsitrust Avatar for cvilledem Avatar for quaker_in_a_basement Avatar for geofu54 Avatar for serendipitoussomnambulist Avatar for dnl Avatar for josephp55 Avatar for cincypix Avatar for magicmaker Avatar for jinnj Avatar for antisachetdethe Avatar for lcelsie Avatar for professorpoopypants Avatar for birdford Avatar for tiowally Avatar for maximus

Continue Discussion
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Deputy Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: